Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter
Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter
貝爾·波特將Paradigm Biopharmaceuticals的目標股價下調了66%,至每股0.47澳元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊